Oxcarbazepine – psychiatrist point of view. Questions and answers Review article
Article Sidebar
Published:
Sep 30, 2018
Keywords:
bipolar disorder, oxcarbazepine, mood stabilizers
Main Article Content
Abstract
Oxcarbazepine is blocking voltage-dependent sodium and calcium channels. The same mechanism has other antiepileptic drugs effective in bipolar disorder. For this reason, scientific societies indicate oxcarbazepine as an alternative to lithium or valproate (APA 2002) and recommend instead of carbamazepine (Texan algorithm 2000). The daily doses used in randomized studies (up to 2400 mg) were effective and in most cases well tolerated.
Article Details
How to Cite
Sobów, T. (2018). Oxcarbazepine – psychiatrist point of view. Questions and answers. Medycyna Faktow (J EBM), 11(3(40), 245-249. https://doi.org/10.24292/01.MF.0318.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Emrich H.M., Altmann H., Dose M., von Zerssen D.: Therapuetic effect of GABA-ergic drugs in affective disorders. Pharmacol. Biochem. Behav. 1983; 19: 369-372.
2. Mueller A.A., Stoll K.D.: Carbamazepine and oxcarbazepine in the treatment of manic syndromes – studies in Germany. W: Emrich H.M., Okuma T., Mueller A.A. (red.): Anticonvulsants in affective disorders. Excerpta Medica, Amsterdam 1984: 139-147.
3. Emrich H.M.: Studies with oxcarbazepine (TrileptalR) in acute mania. International Clinical Psychopharmacology 1990; 5(Suppl. 1): 83-88.
4. Wagner K.D., Kowatch R.A., Emslie G.J. et al.: A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am. J. Psychiatry 2006; 163(7): 1179-1186.
5. Benedetti A., Lattanzi L., Pini S. et al.: Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J. Affect Disord. 2004; 79: 273-277.
6. Kakkar A.K., Rehan H.S., Unni K.E. et al.: Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur. Psychiatry 2009; 24: 178-182.
7. Yatham L.N., Kennedy S.H., Parikh S.V. et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20(2): 97-170.
8. Hellewell J.S.E.: Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J. Affect Disord. 2002; 72: 23-34.
9. Suppes T., Dennehy E.B., Swann A.C. et al.: Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J. Clin. Psychiatry 2002; 63(4): 288-299.
2. Mueller A.A., Stoll K.D.: Carbamazepine and oxcarbazepine in the treatment of manic syndromes – studies in Germany. W: Emrich H.M., Okuma T., Mueller A.A. (red.): Anticonvulsants in affective disorders. Excerpta Medica, Amsterdam 1984: 139-147.
3. Emrich H.M.: Studies with oxcarbazepine (TrileptalR) in acute mania. International Clinical Psychopharmacology 1990; 5(Suppl. 1): 83-88.
4. Wagner K.D., Kowatch R.A., Emslie G.J. et al.: A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am. J. Psychiatry 2006; 163(7): 1179-1186.
5. Benedetti A., Lattanzi L., Pini S. et al.: Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J. Affect Disord. 2004; 79: 273-277.
6. Kakkar A.K., Rehan H.S., Unni K.E. et al.: Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur. Psychiatry 2009; 24: 178-182.
7. Yatham L.N., Kennedy S.H., Parikh S.V. et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20(2): 97-170.
8. Hellewell J.S.E.: Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J. Affect Disord. 2002; 72: 23-34.
9. Suppes T., Dennehy E.B., Swann A.C. et al.: Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J. Clin. Psychiatry 2002; 63(4): 288-299.